Biomarin Pharmaceutical Analysts Cut Their Forecasts After Downbeat Earnings

Biomarin Pharmaceutical Inc (NASDAQ:BMRN) reported weaker-than-expected earnings for the third quarter on Monday.The company posted quarterly earnings of 12 cents per share which missed the analyst consensus estimate of 37 cents per share. The company reported quarterly sales of $776.133 million which missed the analyst consensus estimate of $780.629 million.BioMarin Pharmaceutical lowered its FY2025 adjusted EPS guidance from $4.40-$4.55 to $3.50-$3.60 but raised its sales guidance from $3.125 billion-$3.2 ...